MAPT and Alzheimer disease: Considering that post-translational modifications of tau protein are different in PSP and AD (258, 259) and other tauopathies, more studies are needed to characterize PSP- and CBD-specific tau strains in CSF and specific assays are then necessary to detect these strains.